Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 03:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade...
October 18, 2025 05:15 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
October 08, 2025 06:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress

Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patientsSupports therapeutic potential of ITM’s proprietary targeted radiotherapeutic agentAbstract receives...
March 13, 2025 06:30 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Updates to Commercial Leadership

Dr. Sebastian Marx, ITM’s chief business officer and member of the Executive Board, is stepping down effective July 20, 2025 after nearly two decades at the company Roger Estafanos, currently U.S....
March 06, 2025 04:30 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference

Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a....
August 09, 2019 15:39 ET | Source: World Food Championships

America’s Best Caviar To Be Featured In World Food Championships' Seafood Finals

DALLAS, Texas, Aug. 09, 2019 (GLOBE NEWSWIRE) -- The World Food Championships (WFC) announced that its Seafood Category will be elevated like never before thanks to its newest sponsor, America’s...
April 04, 2016 11:35 ET | Source: Reliable Water Services

Indiana Challenge Searches for Food/Beverage Biz Concepts

INDIANAPOLIS, IN --(Marketwired - April 04, 2016) - Talented cooks with an inspired food or beverage business concept or early-stage business are invited to enter this year's Hottest Kitchen...